PT2953973T - Agentes de ligação do receptor muscarínico de acetilololina e usos - Google Patents
Agentes de ligação do receptor muscarínico de acetilololina e usosInfo
- Publication number
- PT2953973T PT2953973T PT147033377T PT14703337T PT2953973T PT 2953973 T PT2953973 T PT 2953973T PT 147033377 T PT147033377 T PT 147033377T PT 14703337 T PT14703337 T PT 14703337T PT 2953973 T PT2953973 T PT 2953973T
- Authority
- PT
- Portugal
- Prior art keywords
- receptor binding
- binding agents
- acetylcholine receptor
- muscarinic acetylcholine
- muscarinic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361761136P | 2013-02-05 | 2013-02-05 | |
US201361961058P | 2013-10-03 | 2013-10-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2953973T true PT2953973T (pt) | 2019-10-25 |
Family
ID=50070546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT147033377T PT2953973T (pt) | 2013-02-05 | 2014-02-05 | Agentes de ligação do receptor muscarínico de acetilololina e usos |
Country Status (10)
Country | Link |
---|---|
US (3) | US20150368339A1 (pt) |
EP (2) | EP3590578A1 (pt) |
JP (2) | JP2016512954A (pt) |
AU (1) | AU2014214054B2 (pt) |
CA (1) | CA2900147C (pt) |
DK (1) | DK2953973T3 (pt) |
ES (1) | ES2745772T3 (pt) |
PL (1) | PL2953973T3 (pt) |
PT (1) | PT2953973T (pt) |
WO (1) | WO2014122183A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
GB201601690D0 (en) | 2016-01-29 | 2016-03-16 | Heptares Therapeutics Ltd | G proteins |
EP3565898A4 (en) * | 2017-01-05 | 2021-05-26 | Helix Biopharma Corp. | CAR-VEGFR-2 IMMUNE CELLS FOR CANCER TREATMENT |
JP2020506675A (ja) * | 2017-01-05 | 2020-03-05 | へリックス バイオファーマ コープ. | Vegfr−2抗体 |
CA3069930A1 (en) * | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Cd8 binding agents |
WO2019086548A1 (en) | 2017-10-31 | 2019-05-09 | Vib Vzw | Novel antigen-binding chimeric proteins and methods and uses thereof |
CA3138028A1 (en) | 2019-04-29 | 2020-11-05 | Confo Therapeutics N.V. | Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs |
WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
ES2162863T3 (es) | 1993-04-29 | 2002-01-16 | Unilever Nv | Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. |
FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
JP2000515002A (ja) | 1996-06-27 | 2000-11-14 | フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー | 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子 |
AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
EP1141711A1 (en) | 1999-01-05 | 2001-10-10 | Unilever Plc | Binding of antibody fragments to solid supports |
AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
AP1447A (en) | 1999-04-22 | 2005-08-12 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins. |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
WO2001040310A2 (en) | 1999-11-29 | 2001-06-07 | Unilever Plc | Immobilisation of proteins using a polypeptide segment |
ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
ES2324280T3 (es) | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
WO2001090190A2 (en) | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
EP1360207B1 (en) | 2000-12-13 | 2011-06-22 | Bac Ip B.V. | Protein arrays of camelid heavy-chain immunoglobulin variable domains |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
CA2471116A1 (en) | 2001-12-21 | 2003-07-03 | Serge Muyldermans | Method for cloning of variable domain sequences |
JP2005517674A (ja) | 2002-01-03 | 2005-06-16 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | 腫瘍の処置に有用な新規免疫コンジュゲート |
AU2003286004A1 (en) | 2002-11-08 | 2004-06-07 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
WO2004060965A2 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
CA2512545C (en) | 2003-01-10 | 2015-06-30 | Karen Silence | Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) |
EP2251357A1 (en) | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor |
CA2583017A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
EP2365000A3 (en) | 2005-05-18 | 2013-01-16 | Ablynx N.V. | Improved nanobodiesTM against tumor necrosis factor-alpha |
PL3415535T3 (pl) | 2005-05-20 | 2021-06-14 | Ablynx N.V. | Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja |
AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
AU2008219216A1 (en) | 2007-02-21 | 2008-08-28 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
US20110294983A1 (en) | 2008-12-08 | 2011-12-01 | Complix Nv | Single-chain antiparallel coiled coil proteins |
HUE042919T2 (hu) | 2008-12-19 | 2019-07-29 | Ablynx Nv | Genetikai immunizáció sejthez kapcsolódó antigének - például P2X7, CXCR7 vagy CXCR4 - elleni immunglobulinok elõállítására |
WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
GB201014715D0 (en) * | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
DK2611826T3 (en) | 2010-08-30 | 2017-01-09 | Confometrx Inc | A method and composition for the crystallization of a family-C-GPCR |
US8765414B2 (en) | 2011-03-15 | 2014-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | GPCR fusion protein containing an N-terminal autonomously folding stable domain, and crystals of the same |
EA201391514A1 (ru) | 2011-05-13 | 2014-08-29 | Рецептос, Инк | Новые партнеры слияния для кристаллизации рецепторов, связанных с g-белками |
AU2014211355B2 (en) * | 2013-01-30 | 2017-07-13 | Vib Vzw | Novel chimeric polypeptides for screening and drug discovery purposes |
-
2014
- 2014-02-05 PT PT147033377T patent/PT2953973T/pt unknown
- 2014-02-05 US US14/765,824 patent/US20150368339A1/en not_active Abandoned
- 2014-02-05 CA CA2900147A patent/CA2900147C/en active Active
- 2014-02-05 DK DK14703337.7T patent/DK2953973T3/da active
- 2014-02-05 EP EP19184955.3A patent/EP3590578A1/en active Pending
- 2014-02-05 PL PL14703337T patent/PL2953973T3/pl unknown
- 2014-02-05 AU AU2014214054A patent/AU2014214054B2/en active Active
- 2014-02-05 ES ES14703337T patent/ES2745772T3/es active Active
- 2014-02-05 EP EP14703337.7A patent/EP2953973B1/en active Active
- 2014-02-05 WO PCT/EP2014/052265 patent/WO2014122183A1/en active Application Filing
- 2014-02-05 JP JP2015555753A patent/JP2016512954A/ja active Pending
-
2018
- 2018-03-29 US US15/939,748 patent/US20180222978A1/en not_active Abandoned
-
2019
- 2019-02-22 JP JP2019030146A patent/JP6827485B2/ja active Active
-
2021
- 2021-07-02 US US17/366,755 patent/US20210340249A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2014214054A1 (en) | 2015-08-20 |
JP2019122378A (ja) | 2019-07-25 |
EP2953973B1 (en) | 2019-07-10 |
CA2900147A1 (en) | 2014-08-14 |
WO2014122183A1 (en) | 2014-08-14 |
JP2016512954A (ja) | 2016-05-12 |
AU2014214054B2 (en) | 2018-10-04 |
PL2953973T3 (pl) | 2020-01-31 |
US20180222978A1 (en) | 2018-08-09 |
WO2014122183A9 (en) | 2016-05-26 |
US20150368339A1 (en) | 2015-12-24 |
US20210340249A1 (en) | 2021-11-04 |
EP3590578A1 (en) | 2020-01-08 |
ES2745772T3 (es) | 2020-03-03 |
JP6827485B2 (ja) | 2021-02-10 |
CA2900147C (en) | 2023-09-05 |
EP2953973A1 (en) | 2015-12-16 |
DK2953973T3 (da) | 2019-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1225742A1 (zh) | TGF-β受體II型變體及其用途 | |
HK1219658A1 (zh) | 吡咯並苯並二氮雜卓及其結合物 | |
HK1219651A1 (zh) | 吡咯並苯並二氮雜卓以及其結合物 | |
HK1208038A1 (en) | Anti-lgr5 antibodies and immunoconjugates lgr5 | |
HK1214282A1 (zh) | 抗- 抗體及抗體-藥物綴合物 | |
HK1214140A1 (zh) | 吡咯並苯並二氮雜卓和其結合物 | |
HK1208687A1 (en) | Rspo3 binding agents and uses thereof rspo3 | |
IL234719A0 (en) | Anti-pmel17 antibodies and immunoconjugates | |
HK1210947A1 (en) | Anticholinergic neuroprotective composition and methods | |
SI2958944T1 (sl) | Konjugati protiDLL3-protitelo-PBD in njihove uporabe | |
EP2879708A4 (en) | ANTIBODY AND ANTI-ETBR IMMUNOCONJUGATES | |
IL239643A0 (en) | Converted morphines and their use | |
GB201317982D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
GB201317981D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
EP2829480A4 (en) | FEEDING AND COUNTERING DEVICE FOR MEDICINAL PRODUCTS | |
EP2885318A4 (en) | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF | |
EP2888229A4 (en) | ACETYLCHOLINE NICOTINIC A7 RECEPTOR MODULATORS AND USES THEREOF | |
PT2953973T (pt) | Agentes de ligação do receptor muscarínico de acetilololina e usos | |
GB2513444B (en) | Improved stopper device | |
IL240248A0 (en) | Met-binding substances and their uses | |
GB201318151D0 (en) | Composition and device | |
EP2989089A4 (en) | ACETYLCHOLINE ALPHA7 NICOTINIC RECEPTOR MODULATORS AND USES THEREOF | |
GB201210989D0 (en) | Composition and device | |
AU2013900167A0 (en) | Alpha7 Nicotinic Acetylcholine Receptor Modulators and Uses Thereof-II | |
PL2641462T3 (pl) | Urządzenie wiążące |